Corvista Ensures No Patients Left Behind
Corvista Health hopes to provide an extra layer of certitude for patients suspected of coronary artery disease and pulmonary hypertension. Its FDA-cleared noninvasive test for the point of care expands upon the ECG with additional sensors and AI to rule in or rule out coronary artery disease. A second noninvasive test for patients suspected to have pulmonary hypertension received FDA clearance and Breakthrough Device Designation.
Read Article